P 335 Experimental diabetic retinopathy: Influence of several antiplatelet drugs

e. Then, are not references in the liiratura about th+ posibilitv that the platelet hvperanivitv in diabetic patients is different according to the tvpe of retinqmtbv. The aim d the pmumt studv is tq evatuat4 the platelet function in insulin-dependent diebetes meliitus (IDDM) with different tvpes of retinopatv. &U&A, The study was carried put on 20 healthy vok~ntews IHV), 20 tDDM patients withwt retirmpNbv IDWRI, 16 IDDM patients with background mtirmpathv fD6RI. 25 IDDM patkne with ischasmic-prdiative retinopathv IOIRI, and 19 IDDM patients with exudative mtirmpsthv (DERI. In blood samples. we studied platelet agOm&wnetry Msted in plate&t&h plasma -PRPand whole blood) indumd bv ADP and cdlag%n. platelet production of thromboune 6, ITx6,) and II-thmmbcgtobulin I6TG), platelet releaw of ATP. and ewthracvm uptake of tnimMiM. Em&a. Platdet aporwntion in PRP wa* not statisticallv diem between OWUM fp<O.Zl. In whole blood. the concentration of ADP tumc#L) that inhibiis 50% the maximal pht&t aqpmqation, was 1.61 *0.07 in HV, 1.26*0.00 in DWR,0.62tO.OBinDBR,0.56iD.04inDtR,ond0.36+0.02inDER.Platelet a~rtqattm induced bv edlew! , and the other parameters of platelet activation, &wad a qualitative similar bahwkwr that the ADP-induced pIat& awranatton. Ths ewthmcvta of th4 HV incmaead cdlwen-indwxd datelnt &&ion in FUP bv 23.6 * 1.6%. in DWR bv 27.1 i 2.2%. in. D6R by 30.8~35%. in DIR bv 35.3+3.B%. and in OER bv 46k3.396. Ervthmcvtn uptake of &n~sine &is hipher in.diabetics than. in HV. and th& wen, siqniliativr finssr cwrelatioru bawsen this parameter and all the others that indkxted pktmbt activation. CwM&&n& We conclude that the diibetic Dfatstet hvoeractivitv is related with mythtacyte ftmctlon. perhaps by its hiik capacity if keep out adenosine fmmthemediumintDDMwith re*lorwthv. Mwmr, in whda Mocd. plank4 EXPERIMENTAL DIABETIC RETINOPATHY: INFLUENCE OF SEVERAL ANTIPLATELET DRUGS